📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-12 16:25
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
28 announcements match the current filters (relevance ≥ 5).
DCAL Swiss Unit Completes US FDA Inspection With Zero Form 483 Observations
Dishman Carbogen Amcis Limited's wholly owned subsidiary, CARBOGEN AMCIS AG, has completed its first US FDA inspection at its manufacturing site in Vionnaz, Switzerland, with zero Form 483 observations on September 11, 2026. This successful regulatory clearance supports DCAL's high-margin CDMO and development operations. The company posted TTM revenues of ₹2,902 Cr but incurred a net loss of ₹57.88 Cr in Q1 FY27 (ended June 2026). Clean regulatory compliance at key global sites remains critical to scaling its late Phase 3 and commercial API pipeline.
Confidence: HIGH
What changedCARBOGEN AMCIS AG's Vionnaz facility in Switzerland completed its inaugural US FDA inspection with zero observations (no Form 483).
Why it mattersA zero-observation inspection removes regulatory overhang for Swiss manufacturing operations, facilitating smooth supplies and commercialization of late-phase oncology/ADC projects for US clients.
Form 483 observations: 0TTM Revenue: ₹2902 CrInspection completion date: 11th September 2026
📅 Short termPositive sentiment driver for the stock as zero-observation US FDA inspections at European CDMO sites derisk upcoming customer delivery schedules.
📈 Long termStrengthens CARBOGEN AMCIS AG's standing as a reliable global CDMO partner, aiding commercialization of high-value late Phase 3 pipeline molecules.
⚠ Risk flags
- Quarterly earnings volatility due to contract timing and shipment deferments
- Customer concentration risk in late-phase clinical pipeline
Key Highlights
Subsidiary CARBOGEN AMCIS AG cleared its first US FDA audit at Vionnaz, Switzerland with 0 Form 483 observations.
Inspection concluded on 11th September 2026 without any adverse regulatory findings.
Company serves late Phase 3 oncology and ADC molecules with CDMO segment margins reaching 25%+
Clears regulatory hurdles for commercial-scale supply to the US market from the Vionnaz site.
👀 What to Watch
Track subsequent receipt of the formal Establishment Inspection Report (EIR) from the US FDA and monitor revenue trajectory in the CDMO business during upcoming quarterly results.
DCAL Q1 Concall: ADC Revenue at ₹150 Cr; Over 13 Late-Phase Molecules in Pipeline
Dishman Carbogen Amcis released the transcript of its Q1 FY27 earnings conference call. The company reported ADC (Antibody-Drug Conjugate) revenues of approximately ₹150 crore for the quarter, while overall Q1 EBITDA stood at around ₹60 crore. Management noted that its late-stage pipeline includes over 13 late-phase projects with one recently commercialized molecule following US FDA approval. Additionally, DCAL raised ₹75 crore through 10% NCDs for short-term funding while awaiting ECB refinancing after receiving RBI approval.
Confidence: HIGH
What changedFormal submission of the Q1 FY27 earnings call transcript detailing operational progress, segment revenues, pipeline status, and debt refinancing updates.
Why it mattersProvides visibility into DCAL's high-margin ADC portfolio (~₹150 cr in Q1) and late-stage commercial transitions needed to recover margins from Q1 EBITDA levels (~₹60 cr) toward annual targets.
Q1 ADC Segment Revenue: ₹150 crQ1 EBITDA: ₹60 crShort-term NCD Raised: ₹75 crLate-Phase Pipeline Projects: >13
📅 Short termEarnings sentiment remains subdued following Q1 net losses (-₹57.88 cr), though clarity on pipeline conversion and debt refinancing offers operational visibility.
📈 Long termLong-term recovery hinges on the successful transition of 13+ Phase 3 molecules to commercial manufacturing and operational scaling at the French and Bavla facilities.
⚠ Risk flags
- Quarterly shipment volatility and customer-requested delivery deferments
- Short-term reliance on high-cost NCD debt (10%) pending ECB drawdown
- Client concentration in late-stage molecules
Key Highlights
Total ADC-related revenue (linker, payload, hyper molecule) stood at ~₹150 crore in Q1.
Pipeline expanded to over 13 late-phase projects, including PPQ campaigns and FDA priority-status ADC molecules.
Raised ₹75 crore via 10% NCDs as interim bridge financing pending ECB refinancing, which has received RBI approval.
Completed MFDS South Korea audit for Naroda site and secured two European CEPs from EDQM.
👀 What to Watch
Track the commercialization ramp-up of the newly FDA-approved molecule, completion of the Japanese client co-investment in the next calendar year, and operational timeline of ECB debt refinancing to reduce high-cost borrowing.
DCAL Allots ₹75 Cr Senior Secured NCDs Maturing in February 2028
Dishman Carbogen Amcis Limited (DCAL) has completed the allotment of 7,500 senior, secured, rated, listed Non-Convertible Debentures (NCDs) of face value ₹1,00,000 each, aggregating to ₹75 crore on a private placement basis. The debentures carry a maturity date of February 17, 2028. This ₹75 crore debt raise represents ~12.5% of DCAL's market capitalization (₹599 Cr) and ~11.8% of its existing debt load (₹634 Cr). The capital infusion provides near-term liquidity as the company navigates quarterly operational volatility.
Confidence: HIGH
What changedDCAL completed the private placement allotment of ₹75 crore senior secured non-convertible debentures.
Why it mattersProvides fresh balance sheet liquidity of ₹75 crore, expanding total borrowings (~₹634 Cr prior) to fund ongoing operations and facility ramp-ups.
Issue amount: ₹75,00,00,000Number of NCDs: 7,500Face value per NCD: INR 1,00,000Final maturity date: 17th February, 2028Issue size vs Market cap: ~12.5%Issue size vs Existing debt: ~11.8%
📅 Short termProvides immediate liquidity support without equity dilution, but will incrementally increase finance costs.
📈 Long termServicing and refinancing the debentures by February 2028 will depend on commercialization of late Phase 3 molecules and breakeven at international facilities.
⚠ Risk flags
- Incremental interest expense addition on a balance sheet with ₹634 Cr prior debt
- Earnings volatility following a ₹57.88 Cr net loss in Jun 2026 quarter
Key Highlights
Allotted 7,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable NCDs
Face value of ₹1,00,000 each, aggregating to ₹75,00,00,000 (₹75 Crores)
Final maturity date of the instrument is 17th February, 2028
Allotment approved by the Management Committee of the Board on August 17, 2026
👀 What to Watch
Track DCAL's quarterly EBITDA trajectory and interest coverage ratios to assess debt servicing capacity leading into the FY28 maturity.
DCAL Q1 FY27 EBITDA Plunges 57.3% to ₹60.08 Cr; Posts Net Loss of ₹57.88 Cr on CDMO Deferrals
Dishman Carbogen Amcis reported a weak performance in Q1 FY27, with consolidated revenue declining 4.3% YoY to ₹677.64 Cr (₹6,776.4 mn). Operating EBITDA dropped 57.3% YoY to ₹60.08 Cr as margins compressed to 8.9% from 19.9% in Q1 FY26, resulting in a consolidated net loss of ₹57.88 Cr (vs profit of ₹23.41 Cr in Q1 FY26). The downturn was driven by a 12.6% YoY decline in CDMO revenue due to customer-requested rescheduling of deliverables worth ~CHF 10 mn into H2 FY27, which carried high operating leverage on a fixed-cost base. Marketable Molecules revenue grew 48% YoY to ₹143.26 Cr, while the late Phase III development basket expanded to 13 molecules.
Confidence: HIGH
What changedDCAL released its Q1 FY27 investor presentation highlighting a quarterly swing into a ₹57.88 Cr net loss caused by CDMO project deliverable deferrals.
Why it mattersThe sharp drop in EBITDA margins from 19.9% to 8.9% underscores the operating leverage vulnerability in DCAL's CDMO segment when deliveries face timing shifts.
Q1 FY27 Net Revenue: ₹6,776.4 mnQ1 FY27 EBITDA: ₹600.8 mnQ1 FY27 Net Loss: ₹578.8 mnDeferred CDMO Deliverables: approx CHF 10 mnNet Debt (as of June 2026): CHF 153.6 mn
📅 Short termNear-term stock performance may face pressure due to the sharp margin contraction and net loss, pending clarity on H2 execution.
📈 Long termLong-term trajectory depends on scaling the Bavla site, turnaround at the French injectable facility by FY27, and commercial transitions from its 13 Phase III molecules.
⚠ Risk flags
- High quarterly earnings volatility due to client-requested delivery deferrals in the CDMO business
- Operating deleverage due to high fixed employee and overhead costs
- Foreign exchange volatility with a notional forex loss of ₹11.73 Cr recorded in Q1 FY27
Key Highlights
Q1 FY27 Net Revenue declined 4.3% YoY to ₹6,776.4 mn vs ₹7,080.5 mn in Q1 FY26
EBITDA fell 57.3% YoY to ₹600.8 mn, with EBITDA margin contracting by 1,100 bps YoY to 8.9%
Consolidated Net Loss came in at ₹578.8 mn compared to a net profit of ₹234.1 mn in Q1 FY26
CDMO segment revenue fell 12.6% YoY to ₹5,343.8 mn due to client-requested deferrals of ~CHF 10 mn into H2
Net debt stood at CHF 153.6 mn as of June 30, 2026, up from CHF 146.8 mn as of March 31, 2026
👀 What to Watch
Watch for the execution and margin recovery of the deferred ~CHF 10 mn CDMO orders in H2 FY27, along with Phase III clinical trial outcomes across the 13 pipeline molecules.
DCAL Posts Q1 Net Loss of ₹57.88 Cr vs Profit of ₹23.41 Cr YoY; Revenue Drops to ₹677.64 Cr
Dishman Carbogen Amcis reported a consolidated net loss of ₹57.88 Cr for Q1 ended June 30, 2026, slipping from a net profit of ₹23.41 Cr in Q1 FY26 and ₹21.74 Cr in Q4 FY26. Consolidated revenue from operations fell 4.29% YoY to ₹677.64 Cr compared to ₹708.05 Cr in the corresponding previous period. Operating margin compressed sharply to 8.87% compared to 19.87% in Q1 FY26, heavily pressured by elevated employee benefit expenses of ₹389.10 Cr. Diluted EPS for the quarter dropped to ₹(3.69) from ₹1.49 in Q1 FY26.
Confidence: HIGH
What changedDCAL posted a consolidated net loss of ₹57.88 Cr for Q1 ended June 30, 2026, driven by top-line softness and steep margin compression.
Why it mattersThe performance underscores the company's quarterly revenue volatility and high fixed cost structure, creating short-term earnings pressure until late-phase molecules reach commercial production.
Consolidated Revenue: ₹677.64 CrConsolidated Net Loss: ₹(57.88) CrOperating Margin: 8.87%Diluted EPS: ₹(3.69)Q1 Revenue vs TTM Revenue: ~23.1%Debt-Equity Ratio: 0.48
📅 Short termLikely to face negative market sentiment due to the unexpected swing into operating and net losses along with a 1,100 bps margin contraction YoY.
📈 Long termRecovery hinges on transitioning late Phase 3 CDMO pipeline molecules into commercial supply, scaling integrated capacity at the Bavla site, and achieving operational breakeven at the French facility.
⚠ Risk flags
- CDMO revenue volatility from customer shipment deferments
- Margin contraction due to elevated employee benefit and operating expenses
- Client concentration risk in late-phase clinical supply contracts
Key Highlights
Consolidated revenue from operations declined 4.29% YoY to ₹677.64 Cr (vs ₹708.05 Cr in Q1 FY26 and ₹851.40 Cr in Q4 FY26)
Swung to a net loss of ₹57.88 Cr from a net profit of ₹23.41 Cr in Q1 FY26
Operating EBITDA margin shrank to 8.87% vs 19.87% in Q1 FY26 and 19.14% in Q4 FY26
Diluted EPS declined to ₹(3.69) per share compared to ₹1.49 in Q1 FY26
Total expenses stood elevated at ₹745.33 Cr, with employee benefit costs at ₹389.10 Cr
👀 What to Watch
Monitor management commentary on customer shipment deferrals, commercialization milestones for late Phase 3 oncology/ADC molecules, and the margin ramp-up timeline at the Bavla and French facilities.
₹75 Cr Senior Secured NCD Issuance Approved at 10% Coupon
Dishman Carbogen Amcis Limited (DCAL) has approved the private placement of Senior, Secured, Rated NCDs aggregating up to ₹75 crore. The debt carries a 10.00% annual coupon with quarterly interest payments and a short tenure of 18 months, maturing in February 2028. The issuance is secured by a 1.1x cover, primarily through a mortgage on 1,71,476 sq mtrs of land in Bavla, Ahmedabad, held by a subsidiary. This fundraise is relatively small, representing approximately 2.56% of the company's TTM revenue.
Confidence: HIGH
What changedThe company has initiated a new ₹75 crore secured debt issuance via private placement, adding to its existing debt profile of ₹634 crore.
Why it mattersWhile the amount is not large enough to significantly alter the balance sheet, it confirms the company's ability to access debt markets at a 10% cost to manage its liquidity and operational requirements.
Issue Size: ₹75 CrCoupon Rate: 10.00% p.a.Issue vs TTM Revenue: 2.56%Issue vs Total Debt: 11.83%Security Cover: 1.1xTenure: 18 months
📅 Short termThe market is likely to view this as a routine liquidity management exercise. No major price movement is expected solely based on this fundraise.
📈 Long termLimited structural impact. The long-term trajectory depends on the commercialization of late-phase molecules and achieving profitability at the French facility by FY27.
⚠ Risk flags
- Interest cost (10%) exceeds current ROCE (1.0%)
- Security involves assets of a subsidiary (Dishman Infrastructure Limited)
- Bullet repayment risk in 18 months
Key Highlights
Issuance of up to 7,500 NCDs with a face value of ₹1,00,000 each, totaling ₹75 crore.
Fixed coupon rate of 10.00% p.a. to be paid on a quarterly basis.
Short-term tenure of 18 months with a bullet repayment scheduled for February 17, 2028.
Security includes a 1.1x cover backed by a mortgage on 1,71,476 sq mtrs of land in Bavla and a corporate guarantee from Dishman Infrastructure Limited.
👀 What to Watch
Investors should monitor the utilization of these funds, specifically whether they are for refinancing existing debt or for working capital to support the Bavla facility ramp-up. The 10% interest cost is significant given the company's current ROCE of 1.0%.
DCAL FY26 Revenue Grows 8% to ₹2,932 Cr; Board Approves ₹2,452 Cr ECB from Promoter
Dishman Carbogen Amcis (DCAL) reported a steady FY26 performance with consolidated revenue rising 8% YoY to ₹2,931.90 crore. Profit Before Tax (PBT) showed a significant recovery, jumping to ₹108.70 crore from ₹37.42 crore in the previous year. A major highlight is the board's approval to raise up to CHF 200 million (approx. ₹2,452 crore) via External Commercial Borrowings (ECB) from its promoter group at a competitive rate of ~4% p.a. to refinance existing high-cost debt. To facilitate this, the company is seeking to increase its borrowing limits from ₹1,700 crore to ₹4,000 crore.
Key Highlights
Consolidated revenue for FY26 reached ₹2,931.90 crore, up from ₹2,711.50 crore in FY25.
Profit Before Tax (PBT) surged to ₹108.70 crore in FY26 compared to ₹37.42 crore in the previous fiscal year.
Approved a massive fundraise of up to CHF 200 million (~₹2,452 crore) from promoter entity Aamanya AG to refinance existing debt.
The ECB carries a favorable interest rate of SARON + 400 bps (approx. 4% p.a.) with a 10-year maturity.
Proposed increasing the company's total borrowing limit significantly from ₹1,700 crore to ₹4,000 crore.
👀 What to Watch
Investors should monitor the successful execution of the ECB as the transition from high-cost rupee debt to low-cost foreign currency debt (~4%) is expected to significantly reduce finance costs and boost net margins.
DCAL Shareholders Approve Borrowing Limit Increase and ECB Loan from Promoter Group
Dishman Carbogen Amcis Limited (DCAL) held an Extra-Ordinary General Meeting on June 19, 2026, where shareholders approved two significant financial resolutions. The company received a mandate to increase its borrowing limits under Section 180(1)(c) of the Companies Act, 2013. Additionally, shareholders approved a Material Related Party Transaction involving an External Commercial Borrowing (ECB) loan from Aamanya AG, a promoter group entity. These approvals provide the company with the necessary headroom to raise additional capital through debt.
Key Highlights
Shareholders passed a Special Resolution to increase the company's borrowing limits.
Approval granted for an External Commercial Borrowing (ECB) loan from promoter group entity Aamanya AG.
The ECB loan is classified as a Material Related Party Transaction under SEBI regulations.
All resolutions were passed with the requisite majority via remote e-voting and electronic voting during the EGM.
The meeting was held via Video Conferencing and concluded within 25 minutes on June 19, 2026.
👀 What to Watch
Investors should wait for the disclosure of the specific borrowing limit amount and the interest rate terms of the ECB loan from the promoter. It is important to monitor how this increased debt will impact the company's leverage ratios and future interest obligations.
DCAL Shareholders Approve Increased Borrowing Limits and ECB Loan from Promoter Group
Dishman Carbogen Amcis Limited (DCAL) held an Extraordinary General Meeting on June 19, 2026, where shareholders approved two significant financial resolutions. The company received authorization to increase its borrowing limits under Section 180(1)(C) of the Companies Act, 2013. Additionally, shareholders approved a Material Related Party Transaction involving a loan from Aamanya AG, a promoter group entity, via the External Commercial Borrowings (ECB) route. These moves indicate a strategic push to secure additional capital for operations or expansion.
Key Highlights
Shareholders approved a Special Resolution to increase the company's borrowing limits.
Approval granted for an Ordinary Resolution to avail a loan from Aamanya AG, a Promoter Group Entity.
The loan from Aamanya AG will be processed through the External Commercial Borrowings (ECB) route.
The ECB loan is classified as a Material Related Party Transaction.
The EGM was conducted via Video Conferencing (VC) and concluded within 25 minutes.
👀 What to Watch
Investors should monitor the specific quantum of the increased borrowing limit and the interest rate terms of the ECB loan from the promoter group to evaluate the impact on the company's leverage and interest expense.
Dishman Carbogen Amcis Allots 1,800 NCDs Worth ₹18 Crore via Private Placement
Dishman Carbogen Amcis Limited (DCAL) has approved the allotment of 1,800 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures (NCDs). Each debenture has a face value of ₹1,00,000, resulting in a total fundraise of ₹18 crore. This issuance is part of a larger board-approved plan to raise up to ₹150 crore through debt instruments. The NCDs are issued on a private placement basis and have a maturity date of December 9, 2027.
Key Highlights
Allotment of 1,800 Senior Secured NCDs with a face value of ₹1,00,000 each.
Total amount raised in this tranche aggregates to ₹18,00,00,000 (₹18 crore).
The debentures are issued on a private placement basis and will be listed on the exchanges.
The final maturity of the instrument is set for December 9, 2027, or an earlier redemption date.
This allotment follows a prior board approval from March 2026 for a total debt raise of up to ₹150 crore.
👀 What to Watch
Investors should monitor the company's overall leverage and interest coverage ratios as it continues to draw down on its ₹150 crore debt approval. While the current ₹18 crore raise is relatively small, the terms of the secured debt reflect the company's ongoing capital management strategy.
Dishman Carbogen Amcis to Hold EGM on June 19 to Increase Borrowing Limits and Avail ECB Loan
Dishman Carbogen Amcis Limited (DCAL) has scheduled an Extra-Ordinary General Meeting (EGM) for June 19, 2026, to seek shareholder approval for significant financial changes. The company intends to increase its borrowing limits and secure a loan from a Promoter Group Entity through the External Commercial Borrowings (ECB) route. As a Material Related Party Transaction, the ECB loan requires an Ordinary Resolution from shareholders. This move indicates a strategic need for additional liquidity, potentially for debt management or operational funding.
Key Highlights
Extra-Ordinary General Meeting (EGM) to be held on June 19, 2026, via Video Conferencing.
Proposal to increase borrowing limits under Section 180(1)(C) of the Companies Act, 2013.
Plan to avail a loan from a Promoter Group Entity via the External Commercial Borrowings (ECB) route.
The ECB loan is classified as a Material Related Party Transaction requiring shareholder approval.
Full details regarding the loan amount and interest rates will be disclosed in the upcoming EGM Notice.
👀 What to Watch
Investors should carefully examine the EGM notice for the specific quantum of the borrowing limit increase and the terms of the promoter loan. It is crucial to assess the impact of additional debt on the company's leverage and interest coverage ratios.
DCAL FY26 Revenue Grows 8% to ₹29,319 Mn; PAT Surges to ₹974.5 Mn
Dishman Carbogen Amcis (DCAL) reported a steady 8.1% YoY revenue growth for FY26, reaching ₹29,319 million, driven by both CDMO and Marketable Molecules segments. The company achieved a significant turnaround in profitability, with PAT rising to ₹974.5 million from just ₹32.4 million in FY25. Full-year EBITDA margins improved to 19.3%, largely due to a sharp recovery in the Marketable Molecules segment where margins doubled to 18.8%. Additionally, the company successfully reduced its net debt from CHF 157.6 million to CHF 146.8 million during the year.
Key Highlights
FY26 Consolidated Revenue increased 8.1% YoY to ₹29,319 mn, with EBITDA growing 20.6% to ₹5,656 mn.
Marketable Molecules segment margins saw a massive jump from 9.4% in FY25 to 18.8% in FY26.
Net debt (excluding lease liabilities) was reduced by CHF 10.8 mn to end the year at CHF 146.8 mn.
The company maintains a strong development pipeline with 10 molecules currently in Late Phase III.
Q4FY26 revenue grew 18.9% YoY to ₹8,514 mn, although quarterly EBITDA margins compressed slightly to 19.1% from 21.3%.
👀 What to Watch
Investors should focus on the successful margin recovery in the Marketable Molecules segment and the progress of the 10 Late Phase III molecules. The significant PAT growth and debt reduction indicate improving fundamental health, making it a stock to watch for further operational scaling.
DCAL to Raise CHF 200M via Promoter ECB; Borrowing Limit Increased to ₹4,000 Cr
Dishman Carbogen Amcis Limited (DCAL) has approved raising up to CHF 200 million (approximately ₹2,452 Crores) through External Commercial Borrowings (ECB) from its promoter group company, Aamanya AG. This unsecured loan, priced at SARON + 400 bps (currently ~4% p.a.), is intended to refinance existing high-cost rupee debt and fund working capital and capital expenditure. To accommodate this, the board has proposed a significant increase in the company's total borrowing limit from ₹1,700 Crores to ₹4,000 Crores, subject to shareholder approval.
Key Highlights
Approved ECB of up to CHF 200 million (~₹2,452 Crores) from promoter entity Aamanya AG, revised upward from CHF 135 million.
The loan is unsecured with a 10-year tenure and a current all-in-cost interest rate of approximately 4% p.a.
Proposed increase in total borrowing limits under Section 180(1)(c) from ₹1,700 Crores to ₹4,000 Crores.
Proceeds will be used to refinance existing rupee debt at more favorable terms to reduce interest costs.
Board recommended the re-appointment of M/s. T R Chadha & Co. LLP as Statutory Auditors for a second 5-year term.
👀 What to Watch
Investors should view the debt refinancing at lower interest rates as a positive move for margin improvement. Monitor the upcoming EGM for shareholder approval of the increased borrowing limits and the ECB transaction.
DCAL Approves CHF 200M ECB from Promoter and Increases Borrowing Limit to ₹4,000 Cr
Dishman Carbogen Amcis Limited (DCAL) has approved a significant fundraise of up to CHF 200 million (approximately ₹2,452 crores) through External Commercial Borrowings (ECB) from its promoter group company, Aamanya AG. The loan is unsecured with a 10-year maturity and a competitive interest rate of SARON + 400 bps (currently around 4% p.a.). The company plans to use these funds to refinance existing high-cost rupee debt and for working capital requirements. To facilitate this, the Board has also proposed increasing the company's total borrowing limit from ₹1,700 crores to ₹4,000 crores.
Key Highlights
Approved ECB of up to CHF 200 million (~₹2,452 crores) from promoter entity Aamanya AG
Proposed increase in total borrowing limits from ₹1,700 crores to ₹4,000 crores
ECB interest rate set at SARON + 400 bps (approx. 4% p.a.) with a 10-year bullet repayment option
Proceeds to be utilized for refinancing existing rupee debt and funding capital expenditure
Re-appointment of M/s. T R Chadha & Co. LLP as Statutory Auditors for a second 5-year term
👀 What to Watch
Investors should monitor the upcoming EGM for shareholder approval of the ECB and borrowing limit increase. The move to refinance high-cost debt with lower-cost promoter funding is expected to improve interest coverage and cash flow margins.
DCAL to Raise CHF 200M via Promoter ECB; Borrowing Limit Hiked to ₹4,000 Cr
Dishman Carbogen Amcis Limited (DCAL) has approved raising up to CHF 200 million (approximately ₹2,452 Crores) through External Commercial Borrowings (ECB) from its promoter group company, Aamanya AG. To facilitate this, the board has proposed increasing the company's total borrowing limit from ₹1,700 Crores to ₹4,000 Crores. The ECB is priced attractively at SARON + 400 bps (currently ~4% p.a.) with a 10-year maturity, intended to refinance existing high-cost debt and fund capital expenditures. The company also released its FY26 audited financial results with an unmodified audit opinion.
Key Highlights
Approved ECB of up to CHF 200 million (~₹2,452 Crores) from promoter entity Aamanya AG to refinance existing debt.
Proposed a significant hike in borrowing limits from ₹1,700 Crores to ₹4,000 Crores, subject to shareholder approval.
ECB interest rate set at SARON + 400 bps (approx. 4% p.a.) with a 10-year bullet repayment term.
Re-appointment of M/s. T R Chadha & Co. LLP as Statutory Auditors for a second 5-year term.
The refinancing is expected to reduce interest costs and improve the company's debt maturity profile.
👀 What to Watch
Investors should view the transition from high-cost rupee debt to low-cost promoter-backed foreign debt as a positive for margins. Monitor the upcoming EGM for shareholder approval of the increased borrowing limits.
DCAL Subsidiary's Shanghai Site Clears Unannounced NMPA GMP Inspection with Zero Observations
Dishman Carbogen Amcis Limited's subsidiary, CARBOGEN AMCIS (Shanghai), successfully completed an unannounced GMP inspection by China's NMPA. The inspection, conducted on April 14, 2026, focused on API manufacturing and quality systems, resulting in zero observations. This outcome validates the company's high standards and operational consistency across its global network. The clearance supports DCAL's continued growth in the Chinese market and enhances its reputation as a reliable global outsourcing partner.
Key Highlights
Unannounced NMPA GMP inspection completed successfully on April 14, 2026
Zero observations reported for the Shanghai API manufacturing facility
Inspection covered manufacturing processes, quality control labs, and documentation
Validates the maturity of the company's global Quality System
Supports continued growth in China and international pharmaceutical markets
👀 What to Watch
This regulatory clearance reduces operational risk and confirms the high quality of DCAL's global manufacturing assets. Investors should remain confident in the company's compliance capabilities.
DCAL Secures Waiver for Financial Covenants on ₹50 Crore NCDs for FY26
Dishman Carbogen Amcis Limited (DCAL) has received a waiver from its debenture trustee, Axis Trustee Services Limited, regarding specific financial covenants for the fiscal year ended March 31, 2026. This waiver applies to ₹50 crore worth of senior, secured, rated, listed non-convertible debentures (NCDs). The waived covenants include the Total Net Debt to EBITDA ratio, Adjusted Debt Service Coverage Ratio, and Interest Coverage Ratio. While the Net Debt to Tangible Net Worth remains at 1.75x, these waivers suggest the company may have faced difficulty meeting its original financial performance targets for the year.
Key Highlights
Waiver granted for ₹50 crore NCDs (ISIN INE385W07059) for the financial year ended March 31, 2026.
Total Net Debt to EBITDA covenant of 4x has been waived by the debenture trustee.
Adjusted Debt Service Coverage Ratio (DSCR) requirement of 1.15x and Interest Coverage Ratio of 2x also waived.
Net Debt to Tangible Net Worth covenant remains unchanged at 1.75 times for both Consolidated and Standalone levels.
Consent letter for these amendments was received from Axis Trustee Services Limited on March 31, 2026.
👀 What to Watch
Investors should exercise caution as debt covenant waivers often signal underlying liquidity or profitability pressures. Closely monitor the upcoming FY26 full-year results to assess the company's actual EBITDA and debt-servicing capacity.
DCAL Board Approves ₹150 Crore Fundraise via Non-Convertible Debentures (NCDs)
Dishman Carbogen Amcis Limited (DCAL) has approved the issuance of secured, rated, and listed Non-Convertible Debentures (NCDs) totaling ₹150 crores on a private placement basis. The fundraise is divided into two tranches: ₹100 crores with an 18-month tenure and ₹50 crores (including a ₹15 crore green shoe option) with a 24-month tenure. Both tranches carry a coupon rate of 10.00% per annum, payable quarterly. The debt is secured by a 1.1x cover including promoter properties, personal guarantees, and fixed assets of the company's Bavla property.
Key Highlights
Total fundraise of ₹150 crores through Senior, Secured, Rated, Listed NCDs.
Coupon rate for both tranches is fixed at 10.00% per annum with quarterly interest payments.
₹100 crore tranche features a bullet repayment after 18 months from allotment.
₹50 crore tranche features staggered repayment: 35% at 18 months and 65% at 24 months.
Security cover of 1.1x is provided via promoter property, personal guarantees, and charges on company fixed assets.
👀 What to Watch
Investors should monitor the company's leverage ratios and the specific end-use of these funds to ensure they are being deployed for growth or high-interest debt refinancing. The 10% interest rate is relatively standard for the sector, but the short tenure necessitates strong near-term cash flow management.
DCAL Clarifies Credit Rating Downgrade to 'A' Despite Improving Leverage and Margins
India Ratings & Research (IND-RA) has downgraded Dishman Carbogen Amcis Limited's (DCAL) long-term credit rating from 'A+' to 'A' and short-term rating from 'A1+' to 'A1' with a negative outlook. In response, the company issued a clarification highlighting that its financial health is actually improving, with net leverage dropping from 3.92x in March 2025 to 3.18x in September 2025. DCAL also noted that EBITDA margins for its core operations (excluding specific new sites) have reached 25.68%, which is higher than pre-EDQM observation levels. The company expects consolidated performance to strengthen as its newly re-approved Bavla site and French facility scale up.
Key Highlights
Long-term credit rating downgraded to 'A' with a Negative outlook from 'A+' Stable.
Net leverage improved significantly to 3.18x in Sept 2025 from 3.92x in March 2025.
Net debt excluding Fx impact reduced from ₹16,164 million to ₹14,238 million in six months.
Core EBITDA margins (excluding France and India sites) rose to 25.68% in 6MFY26 vs 24.35% in FY20.
Consolidated EBITDA margins improved to 19.35% in 6MFY26 from 17.40% in FY25.
👀 What to Watch
Investors should closely monitor the operational ramp-up at the Bavla and French sites, as their success is key to improving the consolidated credit profile. While the rating downgrade is a negative signal, the improving leverage and core margin trends suggest the company is on a recovery path.
DCAL Subsidiary Receives GMP Compliance Certificate for Netherlands Site
Dishman Carbogen Amcis Limited's wholly-owned subsidiary, CARBOGEN AMCIS B.V., has received a Certificate of GMP Compliance for its manufacturing site in Veenendaal, Netherlands. The certification was issued by the Health and Youth Care Inspectorate (IGJ), the competent authority in the Netherlands, following a successful inspection. This regulatory milestone confirms that the facility adheres to Good Manufacturing Practice standards required for pharmaceutical production. Such approvals are critical for maintaining operational continuity and serving global pharmaceutical clients from European facilities.
Key Highlights
Wholly-owned subsidiary CARBOGEN AMCIS B.V. secured GMP compliance on February 20, 2026.
The certification specifically covers the Veenendaal site located in the Netherlands.
Approval was granted by the Health and Youth Care Inspectorate (IGJ), a key European regulator.
The compliance ensures the facility meets international quality standards for pharmaceutical manufacturing.
👀 What to Watch
Investors should view this as a positive development that reduces regulatory risk and supports the company's high-margin European operations. Maintain a long-term outlook as the company continues to validate its manufacturing capabilities in regulated markets.
